Request Demo
Last update 08 May 2025
IL-23 x OX40L x IL36G
Last update 08 May 2025
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
NCT03739931
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
NCT02872025
Testing the Ability of Immunotherapy to Alter the Tumor Immune MicroEnvionment (TIME) and Reduce or Eradicate High Risk DCIS
100 Clinical Results associated with IL-23 x OX40L x IL36G
Login to view more data
100 Translational Medicine associated with IL-23 x OX40L x IL36G
Login to view more data
Login to view more data
30 Jan 2019Science Translational MedicineQ1 · MEDICINE
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Q1 · MEDICINE
Article
Author: Iliou, Maria S. ; Musenge, Faith ; Frederick, Joshua P. ; Zacharek, Sima J. ; Bailey, Dyane ; Karp, Russell ; Hewitt, Susannah L. ; Burke, Kristine ; Apte, Ameya ; Su, Stephen V. ; Bai, Ailin ; MacLean, Graham ; Farlow, Samuel J. ; Arnold, Kristen ; Ichikawa, Kana ; Bhatt, Khushbu ; Khatwani, Nikhil ; Zielinski, John ; Davis, Ashley ; Garnaas, Maija
Analysis
Perform a panoramic analysis of this field.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free